dGH Screen allows researchers to visualize the structure of the human genome and discover variations in a completely de novo fashion at a resolution of 5 kilobases, the company said. Importantly, the technology does not require bioinformatic methods to recalculate structure from pooled, digested DNA, which often leads to false negative and false positive results for structural variation.

KromaTiD has signed deals with several partners conducting preliminary studies analyzing genomic structural variation in a variety of contexts, including rare disease, radiation exposure, and CRISPR Cas-9 genome editing.

KromaTiD's dGH Screen is available for researchers developing therapies based on CRISPR-Cas9 and other gene editing systems, screening patients for the root causes of rare diseases or hematological cancers, and for qualifying the products of cellular engineering methods.

Next-generation gene therapy points to base editing
Base editing has emerged as a new player in the gene therapy arena, with rapid advances in technology and evidence of proof of concept in rare genetic...

CRISPR-based method can speed the identification of disease-causing genes
A new CRISPR gene editing screening method can be used to link phenotype and genotype in animal models. The method was efficiently deployed in zebrafish...

Atum issued patents for genome engineering
The U.S. Patent and Trademark Office has issued three patents to bioengineering solutions provider Atum. The newly issued patents cover three novel transposase/transposon...

Prime editing shows promise for complex diseases like cystic fibrosis
Researchers have demonstrated that prime editing -- a newer version of CRISPR-Cas9 gene editing -- can be successfully employed to correct gene mutations...

KromaTiD launches new genome assay
KromaTiD announced the launch of its new product, dGH In-Site, a single-cell, high-resolution, genome-wide DNA insert tracking assay.